Literature DB >> 21824671

"Angiographic late catch-up" phenomenon after sirolimus-eluting stent implantation.

Tae-Hyun Yang1, Doo-Il Kim, Han-Young Jin, Young-Wan Cho, Sang Ryul Chung, Dong-Kie Kim, Yong-Bok Kim, Jae-Sik Jang, Ung Kim, Sang-Hoon Seol, Dae-Kyeong Kim, Dong-Soo Kim.   

Abstract

BACKGROUND: Although several randomized trials have shown that sirolimus-eluting stent (SES) substantially reduces in-stent restenosis, recent studies have suggested the possibility of late catch-up after SES implantation. We investigated long-term angiographic outcomes after SES implantation in real-world practice.
METHODS: This study was conducted on 195 patients with 253 lesions who underwent the first and long-term angiographic follow-up after SES implantation. First follow-up was done at near 6 months after SES implantation. Long-term angiographic follow-up was defined as that performed at least 36 months after index procedure. Angiographies in patients who experienced target lesion revascularization at the time of the first angiographic follow-up were excluded from the current analysis.
RESULTS: Minimal luminal diameter at long-term angiographic follow-up was significantly smaller compared with that at the first follow-up (2.21 ± 0.65 vs. 2.40 ± 0.55, p<0.001). In-stent late lumen loss between the first and long-term follow-up tended to be larger compared with that between SES implantation and the first follow-up (0.19 ± 0.47 vs. 0.15 ± 0.39, p=0.298). There was a trend for increased incidence of coronary artery aneurysm (1.6% and 7.5% at the first and long-term follow-up) and stent fracture (4.3% and 10.3%). Two stent aneurysms and one stent fracture were related with definite very late stent thrombosis.
CONCLUSION: An "angiographic late catch-up" phenomenon and a trend toward increased incidence of coronary artery aneurysm and stent fracture were found at a median 46.5-month angiographic follow-up compared with a median 6-month follow-up.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824671     DOI: 10.1016/j.ijcard.2011.03.024

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study.

Authors:  Naoto Tama; Hiroyasu Uzui; Yuki Horita; Masanobu Namura; Hiroshi Tada
Journal:  Heart Vessels       Date:  2017-07-07       Impact factor: 2.037

2.  Three-year clinical outcomes of a sirolimus-eluting bioresorbable scaffold (XINSORB) and a metallic stent to treat coronary artery stenosis.

Authors:  Yizhe Wu; Zhifeng Yao; Jiasheng Yin; Jiahui Chen; Juying Qian; Li Shen; Lei Ge; Junbo Ge
Journal:  Ann Transl Med       Date:  2020-11

3.  Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents.

Authors:  Liefke C van der Heijden; Marlies M Kok; Paolo Zocca; Hanim Sen; Marije M Löwik; Silvia Mariani; Frits H A F de Man; Marc Hartmann; Martin G Stoel; K Gert van Houwelingen; J Hans W Louwerenburg; Gerard C M Linssen; Carine J M Doggen; Jan G Grandjean; Clemens von Birgelen
Journal:  J Am Heart Assoc       Date:  2018-01-30       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.